Emerging roles of chemokines in prostate cancer

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 663-673

  Vindrieux, David ^a,b   Escobar, Pauline ^a,b   Lazennec, Gwendal ^a,b  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR6; CXCL1 CHEMOKINE; CXCL14 CHEMOKINE; CXCL2 CHEMOKINE; DUFFY BINDING PROTEIN; EOTAXIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VASCULOTROPIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CHEMOTAXIS; CYTOKINE PRODUCTION; HUMAN; INCIDENCE; LYMPHOCYTIC INFILTRATION; METASTASIS; MICROENVIRONMENT; PLEIOTROPY; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; TUMOR LOCALIZATION;

CARCINOMA; CHEMOKINES; DISEASE PROGRESSION; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 72749094682     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0109     Document Type: Review

References (80)

1. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP & Schwartz SA 2004 Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Research 64 5311-5321. (Pubitemid 39006551)
2. Akashi T, Koizumi K, Nagakawa O, Fuse H & Saiki I 2006 Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncology Reports 16 831-836.
3. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y & Fuse H 2008 Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Science 99 539-542. (Pubitemid 351228571)
4. Ali S & Lazennec G 2007 Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Reviews 26 401-420. (Pubitemid 350115103)
5. Ao M, Franco OE, Park D, Raman D, Williams K & Hayward SW 2007 Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Research 67 4244-4253. (Pubitemid 46815071)
6. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB & Lokeshwar BL 2007 Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Research 67 6854-6862.
7. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27 1883-1893.
8. Barclay WW, Woodruff RD, Hall MC & Cramer SD 2005 A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 146 13-18.
9. Begley L, Monteleon C, Shah RB, Macdonald JW & Macoska JA 2005 CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4 291-298. (Pubitemid 43918278)
10. Begley LA, Kasina S, MacDonald J & Macoska JA 2008a The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 43 194-199.
11. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM & Macoska JA 2008b CXCL5 promotes prostate cancer progression. Neoplasia 10 244-254. (Pubitemid 351328584)
12. Berquin IM, Min Y, Wu R, Wu H & Chen YQ 2005 Expression signature of the mouse prostate. Journal of Biological Chemistry 280 36442-36451.
13. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ et al. 2004 Human prostate cancer risk factors. Cancer 101 2371-2490. (Pubitemid 39505434)
14. Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR, Weissleder R & Luster AD 2006 Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. Journal of Immunology 177 6991-6998. (Pubitemid 44715065)
15. Caruso DJ, Carmack AJK, Lokeshwar VB, Duncan RC, Soloway MS & Lokeshwar BL 2008 Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clinical Cancer Research 14 4111-4118.
16. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD & Cher ML 2006 CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66 32-48. (Pubitemid 43005947)
17. Craig M, Ying C & Loberg RD 2008 Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. Journal of Cellular Biochemistry 103 1-8.
18. Devlin HL & Mudryj M 2009 Progression of prostate cancer: multiple pathways to androgen independence. Cancer Letters 274 177-186.
19. Dowsland MH, Harvey JR, Lennard TW, Kirby JA & Ali S 2003 Chemokines, breast cancer: a gateway to revolutionary targeted cancer treatments? Current Medicinal Chemistry 10 579-592.
20. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, Jonas D & Blaheta RA 2006a Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sciences 78 1784-1793. (Pubitemid 43295576)
21. Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D et al. 2006b CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins. Neoplasia 8 290-301.
22. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP & Kreutzer DL 1998 Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51 161-167. (Pubitemid 28092530)
23. Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, Christoph F, Miller K, Scheibenbogen C & Keilholz U 2008 Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. Journal of Cancer Research and Clinical Oncology 134 1181-1189.
24. Gingrich JR & Greenberg NM 1996 A transgenic mouse prostate cancer model. Toxicologic Pathology 24 502-504. (Pubitemid 26274861)
25. Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z & Schall TJ 2000 Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. Journal of Immunology 164 2851-2856. (Pubitemid 30148939)
26. Gouwy M, Struyf S, Proost P & Van Damme J 2005 Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine & Growth Factor Reviews 16 561-580. (Pubitemid 41505517)
27. Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, Proost P & Van Damme J 2008 Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Molecular Pharmacology 74 485-495.
28. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y & Dahiya R 2007 CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clinical Cancer Research 13 5056-5062. (Pubitemid 47502070)
29. Hu W, Zhen X, Xiong B, Wang B, Zhang W & Zhou W 2008 CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Science 99 1362-1369. (Pubitemid 351761725)
30. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA & Reeder JE 2005 Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. American Journal of Pathology 166 1807-1815. (Pubitemid 40734403)
31. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA et al. 2000 Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical Cancer Research 6 2104-2119. (Pubitemid 30305111)
32. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O & Fatatis A 2008 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Research 68 1715-1722.
33. Javidan J, Deitch AD, Shi XB & de Vere White RW 2005 The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Investigation 23 520-528. (Pubitemid 41463868)
34. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C & Thun MJ 2006 Cancer statistics, 2006. CA: A Cancer Journal for Clinicians 56 106-130.
35. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N & Fidler IJ 2001 Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3 33-42. (Pubitemid 32201608)
36. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K & Agrawal KC 2005 Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1α (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-κB activation. Cancer Research 65 9891-9898.
37. Lazennec G & Jorgensen C 2008 Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 26 1387-1394.
38. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP & Kung HJ 2004 Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23 2197-2205. (Pubitemid 38482534)
39. Lehrer S, Diamond EJ, Mamkine B, Stone NN & Stock RG 2004 Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technology in Cancer Research & Treatment 3 411. (Pubitemid 39391995)
40. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK & Pienta KJ 2006 CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8 578-586. (Pubitemid 44061313)
41. Loberg RD, Ying C, Craig M, Yan L, Snyder LA & Pienta KJ 2007 CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9 556-562. (Pubitemid 47121829)
42. Logothetis CJ & Lin SH 2005 Osteoblasts in prostate cancer metastasis to bone. Nature Reviews. Cancer 5 21-28. (Pubitemid 40052322)
43. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z & Zhang J 2006 Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66 1311-1318. (Pubitemid 44384308)
44. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD & Zhang J 2007a Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Research 67 3646-3653. (Pubitemid 46762149)
45. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z & Zhang J 2007b CCR2 expression correlates with prostate cancer progression. Journal of Cellular Biochemistry 101 676-685. (Pubitemid 46698852)
46. Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA & Mueller C 1996 Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. American Journal of Pathology 149 501-509. (Pubitemid 26256338)
47. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S et al. 1999 Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. American Journal of Pathology 154 1503-1512. (Pubitemid 29226445)
48. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R & Waugh DJ 2005 Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clinical Cancer Research 11 4117-4127.
49. Nagpal ML, Davis J & Lin T 2006 Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochimica et Biophysica Acta 1762 811-818. (Pubitemid 44403048)
50. Nibbs RJ, Wylie SM, Pragnell IB & Graham GJ 1997 Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1α receptors, CCR-1, CCR-3, and CCR-5. Journal of Biological Chemistry 272 12495-12504.
51. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD & Cunha GR 1999 Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research 59 5002-5011.
52. Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, Lu ZH, Hesselgesser J et al. 1995 The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. Journal of Experimental Medicine 181 1311-1317.
53. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB et al. 2008 The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways. Prostate 69 480-493.
54. Proudfoot AE, Handel TM, Johnson Z, Lau EK, Li Wang P, Clark-Lewis I, Borlat F, Wells TN & Kosco-Vilbois MH 2003 Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. PNAS 100 1885-1890. (Pubitemid 36254543)
55. Rajarathnam K, Sykes BD, Kay CM, Dewald B, Geiser T, Baggiolini M & Clark-Lewis I 1994 Neutrophil activation by monomeric interleukin-8. Science 264 90-92.
56. Reiland J, Furcht LT & McCarthy JB 1999 CXC-chemokines, stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 41 78-88. (Pubitemid 29446962)
57. Richmond A 2002 NF-κB, chemokine gene transcription and tumour growth. Nature Reviews. Immunology 2 664-674. (Pubitemid 37328724)
58. Rossi D & Zlotnik A 2000 The biology of chemokines and their receptors. Annual Review of Immunology 18 217-242.
59. Schauer IG, Ressler SJ & Rowley DR 2008a Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate 69 373-384.
60. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD & Rowley DR 2008b Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72 205-213.
61. Schwarze SR, Luo J, Isaacs WB & Jarrard DF 2005 Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64 67-74. (Pubitemid 40734740)
62. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG & Waugh DJ 2008 Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29 1148-1156. (Pubitemid 351958693)
63. Shen H, Schuster R, Lu B, Waltz SE & Lentsch AB 2006a Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66 1721-1728. (Pubitemid 44893898)
64. Shen H, Schuster R, Stringer KF, Waltz SE & Lentsch AB 2006b The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB Journal 20 59-64. (Pubitemid 43100476)
65. Shulby SA, Dolloff NG, Stearns ME, Meucci O & Fatatis A 2004 CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Research 64 4693-4698. (Pubitemid 38924507)
66. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H et al. 2005 Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research 20 318-329.
67. Szabo MC, Soo KS, Zlotnik A & Schall TJ 1995 Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor. Journal of Biological Chemistry 270 25348-25351.
68. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS & McCauley LK 2002 Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research 62 1832-1837. (Pubitemid 34408510)
69. Taplin ME 2007 Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nature Clinical Practice. Oncology 4 236-244. (Pubitemid 46510533)
70. Thelen M 2001 Dancing to the tune of chemokines. Nature Immunology 2 129-134.
71. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ & Pettaway CA 2005 Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64 40-49. (Pubitemid 40734737)
72. Vaday GG, Peehl DM, Kadam PA & Lawrence DM 2006 Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 124-134. (Pubitemid 43191234)
73. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL & Ralph D 1999 Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53 139-147. (Pubitemid 29016629)
74. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA & Ambs S 2008 Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Research 68 927-936. (Pubitemid 351206772)
75. Wang J, Wang J, Sun Y, Song W, Nor JE, Wang CY & Taichman RS 2005 Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cellular Signalling 17 1578-1592. (Pubitemid 41253997)
76. Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ et al. 2007 A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Research 67 149-159. (Pubitemid 46142770)
77. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R & Taichman RS 2008 The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry 283 4283-4294.
78. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A & St Clair WH 2009 RelB enhances prostate cancer growth: implications for the role of the nuclear factor-κB alternative pathway in tumorigenicity. Cancer Research 69 3267-3271.
79. Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J & Tangrea JA 2006 Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. European Journal of Cancer Prevention 15 249-253. (Pubitemid 43791771)
80. Zhang S, Qi L, Li M, Zhang D, Xu S, Wang N & Sun B 2008 Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. Journal of Experimental and Clinical Cancer Research 27 62.